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place proceeds at an accelerating pace. Medicine is no
exception. How much evidence is needed before a new
technology can be recommended for routine clinical
practice?
The introduction of new technologies into vascular
surgery follows the Technology Hype Cycle described
by Gartner.1 First the emerging technology is
developed and tested in a limited environment.
Second there is an inflated peak of expectation of the
application for the new technology, often fuelled by an
excited press and manufacturers (over-hype). Third
there is a descent into a trough of disillusionment as
the technology fails to meet all expectations and
problems are identified, often compounded by
adverse press comments. Products that pull through
this stage are likely to be successful and after further
development and new definition of application move
up the slope of enlightenment to establish the
appropriate range of application allowing the final
stability for marketing the technology. Much later, in
turn, newer technologies will replace the new
technology.
This cycle almost has been completed for endovas-
cular repair of abdominal aortic aneurysm (EVAR).
The possibility of endovascular repair of aortic
aneurysms was demonstrated first by Volodos and
Parodi in 1986–91.2,3 Five years later, there was an
inflated peak of expectation about the role of EVAR, as
the first phase I trials reached the public domain; level
3 or 4 evidence.4 The companies developing endo-
grafts worked to ensure the visibility of the new
technology and develop their market place. Later still,cture given at European Society of Vascular Surgery,
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as EUROSTAR illustrated the prevalence of problems,
re-interventions and even rupture at long-term follow
up.5,6 There was a trough of disillusionment, with
editorial content sometimes indicating that there
would be no place for EVAR.7 However, between
1994 and 1999, the endografts underwent a process of
continued technological improvement and the 1999
endografts were considered much superior to those
used in 1994. Now, with the technology becoming
stabilized it was time to start randomised controlled
trials, to compare EVAR with the contemporary gold
standard, open surgical repair of abdominal aortic
aneurysm (AAA). The first to start were EVAR 1 in
September 1999 and DREAM in November 1999
enrolling patients with large AAA.8,9 Both these trials
were supported by not-for-profit organizations and
this is important, since industry sponsored trials often
overestimate treatment effect (by about 30%) and
negative trials may not get reported.10 So up the
slope of enlightenment, although it was not until 2004
that the first results, showing that EVAR reduced 30-
day operative mortality by three-fold, were published.
One year later in 2005, mid-term results became
available, showing a persistent reduction in aneur-
ysm-related mortality but no difference in all-cause
mortality. After 16 years, there is clear evidence that
EVAR matches the previous gold standard, open
surgery, and offers benefits with respect to early
recovery and aneurysm-related mortality. Each ran-
domised controlled trial provides level 1b evidence,
synthesis of their similar findings in a meta-analysis
provides the highest level of evidence. However, for
patients unfit for open surgery, the EVAR 2 trial
showed little benefit for EVAR.11 The indications for
the use of EVAR and the potential commercial market
for endografts have been clarified by these random-
ised controlled trials. For now the stable marketEur J Vasc Endovasc Surg 31, 1–2 (2006)
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patients, since currently there is no level 1 evidence to
support the endovascular treatment of either large
AAA in patients unfit for open surgery or AAA
smaller than 5.5 cm in diameter.
The final step in the Hype Cycle is the approval of
EVAR by the regulatory authorities in the different
European countries. Some may not respond with an
immediate answer about the use of EVAR in routine
clinical practice but await longer-term results to the
ascertain more robustly the cost-effectiveness of
EVAR. In this context, it is disconcerting that the
Belgian Health Technology Assessment group already
have decided that financial incentives should be given
to open surgery and that any added costs of EVAR
should be carried by research budgets. The conclusion
is likely to be different in other countries.
Although evidence from randomised clinical trials,
preferably at least two with similar outcome measures,
should be the minimum evidence required before new
technologies are translated into routine clinical
practice, this is far from reality. In 1998, a Dutch trial
showed that routine stenting at iliac angioplasty was
unnecessary and not cost-effective.12 No one has taken
any notice, with the ongoing development of newer
covered stents and drug eluting stents being tested
and marketed. No one has taken up the challenge of
running a trial of endolaser therapy for varicose veins
against the gold standard of surgical stripping.13 High
risk (and high reimbursement) areas appear to be
more likely to reach a randomised controlled trial.
These randomised controlled trials should be open
access, to all qualified practitioners, and can be started
before the technology has fully stabilised. In this way,
recruitment can be maximised and trials will be
started before it is too late (with new technology
introduced without being compared robustly to the
contemporary gold standard), hoping to achieve
results rapidly. Randomised controlled trials have
quite a rigid structure, which makes it difficult to
introduce assessment of new technologies into
ongoing trial collaborations. For carotid disease,
endarterectomy under general anaesthesia is the gold
standard. A trial comparing general and local anaes-
thesia for carotid endarterectomy cannot be modified
to include a carotid artery stenting arm. If the benefits
of new technologies are to be passed on to patients
rapidly, we need to reconsider how current trial
management and steering committees can be diverted
to investigate new technologies as they evolve. Also
patients whom these technologies will benefit should
have a more important role in decision making.Eur J Vasc Endovasc Surg Vol 31, 1 2006It has taken over 16 years to improve the technology
and obtain the evidence for EVAR. We owe it to
patients to speed up the process of evidence. Such an
approach is likely to be welcomed by industry.
Flexibility needs to be introduced into the design of
randomised clinical trials, which should have ‘not-for-
profit support’, open access for participants, an early
start before technology is fully stabilised and more
patient involvement. Could there be a European
Vascular Surgical Clinical Trials Centre whose princi-
pal role was to horizon scan and start the important
trials of emerging technology relevant to vascular
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